https://www.globenewswire.com/news-release/2026/02/24/3243205/0/en/novo-nordisk-triple-agonist-ubt251-delivers-up-to-19-7-mean-weight-loss-after-24-weeks-in-phase-2-trial-in-china.html
Novo Nordisk: Triple agonist UBT251 delivers up to 19.7%
The United Laboratories International Holdings Limited and Novo Nordisk today announced topline results from a Chinese phase 2 trial of UBT251...
novo nordiskup totripleagonistdelivers